ArticleNano letters2025
Optical Nanobubble Amplification Enables Compartment- and Enzyme-Free Digital Attomolar Protein Absolute Quantification.
Article in Nano letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Absolute quantification at the single-protein level is crucial for accurately defining relationships between biomarkers, which are pivotal for disease diagnostics and therapeutic development. While digital detection technologies have achieved single-molecule sensitivity, they often rely on enzymatic amplification and physical compartmentalization, making the process complex and time-consuming. To address these challenges, we developed BEACON (biomarker enumeration via amplified cavitation optical nanobubbles), a compartment- and enzyme-free, high-throughput platform for single-protein counting. BEACON employs antibody-functionalized silica beads and gold nanoparticles to form sandwich complexes with the target proteins. Upon laser excitation, each gold nanoparticle generates a detectable plasmonic nanobubble, providing a robust scattering signal for the digital counting of individual proteins. Using BEACON, we achieved attomolar detection limits for clinically relevant protein biomarkers: PSA (32 aM), COVID-S (123 aM), and RSV fusion (65 aM). BEACON offers a simplified, rapid, and highly sensitive alternative to existing digital immunoassays with significant potential for clinical diagnostics and point-of-care applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.